Skip to main content

Table 1 Baseline patient characteristics

From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

  bb Lapatinib + Capecitabine
Characteristic Brain metastasis (n = 58) No Brain metastasis (n = 128) Pvaluea No Prior capecitabine (n = 95) Prior capecitabine (n = 91) Pvaluea Total (n = 186†)
  No. % No. %   No. % No. %   No. %
Median age, yrs (range) 46.5 (27-70) 49 (27-71) 0.170 48 (27-71) 47 (29-70) 0.960 48 (27-71)
<50 38 (65.5) 67 (52.3) 0.1111 53 (55.8) 52 (57.1) 0.8832 105 (56.2)
≥50 20 (34.5) 61 (47.7)   42 (44.2) 39 (42.9)   82 (43.9)
Hormone receptor
ER + and/or PR+ 28 (49.1) 45 (35.4) 0.103 36 (38.3) 37 (41.1) 0.764 73 (39.7)
ER- and PR- 29 (50.9) 82 (64.6)   58 (61.7) 53 (58.9)   111 (60.3)
Unknown 1 (1.7) 1 (0.8)   1 (1.0) 1 (1.1)   2 (1.1)
No. metastatic sites
1 5 (8.9) 17 (13.6) 0.174 14 (15.2) 8 (9.0) 0.042 22 (12.2)
2 15 (26.8) 47 (37.6)   37 (40.2) 25 (28.1)   62 (34.3)
≥ 3 36 (64.3) 61 (48.8)   41 (44.6) 56 (62.9)   97 (53.6)
Unknown 2 (3.4) 3 (2.3)   3 (3.2) 2 (2.2)   5 (2.7)
Pattern of metastasis
Visceral only 18 (31.6) 56 (45.5) 0.161 34 (37.8) 40 (44.4) 0.617 74 (41.1)
Non-visceral only 8 (14.0) 11 (8.9)   11 (12.2) 8 (8.9)   19 (10.6)
Both 31 (54.4) 56 (45.5)   45 (50.0) 42 (46.7)   87 (48.3)
Unknown 1 (1.7) 5 (3.9)   5 (5.3) 1 (1.1)   6 (3.2)
Prior capecitabine b 30 (51.7) 61 (47.7)   0 (0.0) 91 (48.9)   91 (48.9)
> 3 Prior chemotherapy regimens 22 (37.9) 45 (35.2)   10 (10.5) 57 (62.6)   67 (36.0)
Median duration of trastuzumab, wks (range) 35.4 (4.0-113.6) 20.6 (0.1-105.0) 0.016 27.3 (0.1-104.4) 21.6 (3.0-113.6) 0.252 24.1 (0.1-113.6)
Interval from last dose of trastuzumab prior to study entry, wks
Median (range) 11.6 (2.7-146.6) 20.9 (0.1-172.3) 0.365 7.7 (0.1-172.3) 24.9 (1.4-160.9) 0.001 14.6 (0.1-172.3)
< 4 3 (5.2) 16 (12.6) 0.341 14 (14.7) 5 (5.6) <0.001 19 (10.3)
4 - 8 17 (29.3) 33 (26.0)   37 (39.0) 13 (14.4)   50 (27.0)
>8 38 (65.5) 78 (61.4)   44 (46.3) 72 (80.0)   116 (62.7)
Unknown 0 (0.0) 1 (0.8)   0 (0.0) 1 (1.1)   1 (0.5)
  1. a Fisher’s exact χ2 test for categorical variables and independent t-test for continuous variables; two-sided p-values.
  2. b Included 8 cases who had lapatinib during capecitabine.
  3. Because of few information (only age and study date), 1 patient was excluded.
  4. ‘Unknown’ included missing values.